Page 402 - Williams Hematology ( PDFDrive )

376 Part V: Therapeutic Principles Chapter 23: Hematopoietic Cell Transplantation 377

165. Santos GW, Tutschka PJ, Brookmeyer R, et al: Marrow transplantation for acute non- 192. Duval M, Klein JP, He W, et al: Hematopoietic stem-cell transplantation for acute leu-
lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J kemia in relapse or primary induction failure. J Clin Oncol 28:3730–3738, 2010.
Med 309:1347–1353, 1983. 193. Walter RB, Gooley TA, Wood BL, et al: Impact of pretransplantation minimal residual
166. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia follow- disease, as detected by multiparametric flow cytometry, on outcome of myeloablative
ing a new busulfan and cyclophosphamide regimen. Blood 70:1382–1388, 1987. hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29:1190–
167. Clift RA, Buckner CD, Thomas ED, et al: Marrow transplantation for chronic myeloid 1197, 2011.
leukemia: A randomized study comparing cyclophosphamide and total body irradia- 194. Walter RB, Buckley SA, Pagel JM, et al: Significance of minimal residual disease before
tion with busulfan and cyclophosphamide. Blood 84:2036–2043, 1994. myeloablative allogeneic hematopoietic cell transplantation for AML in first and sec-
168. Pidala J, Kim J, Anasetti C, et al: Pharmacokinetic targeting of intravenous busulfan ond complete remission. Blood 122:1813–1821, 2013.
reduces conditioning regimen related toxicity following allogeneic hematopoietic cell 195. Walter RB, Gyurkocza B, Storer BE, et al: Comparison of minimal residual disease as
transplantation for acute myelogenous leukemia. J Hematol Oncol 3:36, 2010. outcome predictor for AML patients in first complete remission undergoing myeloab-
169. Lee JW, Kang HJ, Lee SH, et al: Highly variable pharmacokinetics of once-daily intra- lative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia
venous busulfan when combined with fludarabine in pediatric patients: Phase I clinical 29:137–144, 2015.
study for determination of optimal once-daily busulfan dose using pharmacokinetic 196. Crocchiolo R, Canevari C, Assanelli A, et al: Pre-transplant 18FDG-PET predicts out-
modeling. Biol Blood Marrow Transplant 18:944–950, 2012. come in lymphoma patients treated with high-dose sequential chemotherapy followed
170. DeLeve LD: Cellular target of cyclophosphamide toxicity in the murine liver: Role of by autologous stem cell transplantation. Leuk Lymphoma 49:727–733, 2008.
glutathione and site of metabolic activation. Hepatology 24:830–837, 1996. 197. Moskowitz CH, Matasar MJ, Zelenetz AD, et al: Normalization of pre-ASCT, FDG-
171. DeLeve LD, Wang X: Role of oxidative stress and glutathione in busulfan toxicity in PET imaging with second-line, non-cross-resistant, chemotherapy programs improves
cultured murine hepatocytes. Pharmacology 60:143–154, 2000. event-free survival in patients with Hodgkin lymphoma. Blood 119:1665–1670, 2012.
172. Rezvani AR, McCune JS, Storer BE, et al: Cyclophosphamide followed by intravenous 198. Akhtar S, Al-Sugair AS, Abouzied M, et al: Pre-transplant FDG-PET-based survival
targeted busulfan for allogeneic hematopoietic cell transplantation: Pharmacokinetics model in relapsed and refractory Hodgkin’s lymphoma: Outcome after high-dose che-
and clinical outcomes. Biol Blood Marrow Transplant 19:1033–1039, 2013. motherapy and auto-SCT. Bone Marrow Transplant 48:1530–1536, 2013.
173. Liu DH, Xu LP, Zhang XH, et al: Substitution of cyclophosphamide in the modified 199. Smeltzer JP, Cashen AF, Zhang Q, et al: Prognostic significance of FDG-PET in relapsed
BuCy regimen with fludarabine is associated with increased incidence of severe pneu- or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy
monia: A prospective, randomized study. Int J Hematol 98:708–715, 2013. and autologous stem cell transplantation. Biol Blood Marrow Transplant 17:1646–1652,
174. Lee JH, Joo YD, Kim H, et al: Randomized trial of myeloablative conditioning regi- 2011.
mens: Busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 200. Wallen H, Gooley TA, Deeg HJ, et al: Ablative allogeneic hematopoietic cell transplan-
31:701–709, 2013. tation in adults 60 years of age and older. J Clin Oncol 23:3439–3446, 2005.
175. Storb R, Yu C, Wagner JL, et al: Stable mixed hematopoietic chimerism in DLA- 201. Corradini P, Zallio F, Mariotti J, et al: Effect of age and previous autologous transplan-
identical littermate dogs given sublethal total body irradiation before and pharmaco- tation on nonrelapse mortality and survival in patients treated with reduced-intensity
logical immunosuppression after marrow transplantation. Blood 89:3048–3054, 1997. conditioning and allografting for advanced hematologic malignancies. J Clin Oncol
176. McSweeney PA, Niederwieser D, Shizuru JA, et al: Hematopoietic cell transplantation 23:6690–6698, 2005.
in older patients with hematologic malignancies: Replacing high-dose cytotoxic ther- 202. Sorror ML, Sandmaier BM, Storer BE, et al: Long-term outcomes among older patients
apy with graft-versus-tumor effects. Blood 97:3390–3400, 2001. following nonmyeloablative conditioning and allogeneic hematopoietic cell transplan-
177. Storb R, Gyurkocza B, Storer BE, et al: Graft-versus-host disease and graft-versus- tation for advanced hematologic malignancies. JAMA 306:1874–1883, 2011.
tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 31:1530– 203. Brunner AM, Kim HT, Coughlin E, et al: Outcomes in patients age 70 or older under-
1538, 2013. going allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
178. Sorror ML, Storer BE, Sandmaier BM, et al: Five-year follow-up of patients with Biol Blood Marrow Transplant 19:1374–1380, 2013.
advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell 204. Sorror ML, Storb RF, Sandmaier BM, et al: Comorbidity-age index: A clinical mea-
transplantation after nonmyeloablative conditioning. J Clin Oncol 26:4912–4920, 2008. sure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol
179. Rezvani AR, Storer B, Maris M, et al: Nonmyeloablative allogeneic hematopoietic cell 32:3249–3256, 2014.
transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lym- 205. Kumar SK, Dingli D, Lacy MQ, et al: Autologous stem cell transplantation in patients of
phoma. J Clin Oncol 26:211–217, 2008. 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J
180. Khouri IF, Keating M, Korbling M, et al: Transplant-lite: Induction of graft-versus- Hematol 83:614–617, 2008.
malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood 206. Badros A, Barlogie B, Siegel E, et al: Autologous stem cell transplantation in elderly
progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol multiple myeloma patients over the age of 70 years. Br J Haematol 114:600–607, 2001.
16:2817–2824, 1998. 207. Deeg HJ, Seidel K, Bruemmer B, et al: Impact of patient weight on non-relapse mortal-
181. Khouri IF, Saliba RM, Erwin WD, et al: Nonmyeloablative allogeneic transplantation ity after marrow transplantation. Bone Marrow Transplant 15:461–468, 1995.
with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed 208. Dickson TM, Kusnierz-Glaz CR, Blume KG, et al: Impact of admission body weight and
follicular lymphoma: 12-year results. Blood 119:6373–6378, 2012. chemotherapy dose adjustment on the outcome of autologous bone marrow transplan-
182. Lan F, Zeng D, Higuchi M, et al: Host conditioning with total lymphoid irradiation and tation. Biol Blood Marrow Transplant 5:299–305, 1999.
antithymocyte globulin prevents graft-versus-host disease: The role of CD1-reactive 209. Gratwohl A, Hermans J, Goldman JM, et al: Risk assessment for patients with chronic
natural killer T cells. Biol Blood Marrow Transplant 9:355–363, 2003. myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leu-
183. Pillai AB, George TI, Dutt S, et al: Host natural killer T cells induce an interleukin-4- kemia Working Party of the European Group for Blood and Marrow Transplantation.
dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects Lancet 352:1087–1092, 1998.
against graft-versus-host disease. Blood 113:4458–4467, 2009. 210. Parimon T, Au DH, Martin PJ, et al: A risk score for mortality after allogeneic hemato-
184. Lowsky R, Takahashi T, Liu YP, et al: Protective conditioning for acute graft-versus-host poietic cell transplantation. Ann Intern Med 144:407–414, 2006.
disease. N Engl J Med 353:1321–1331, 2005. 211. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-spe-
185. Kohrt HE, Turnbull BB, Heydari K, et al: TLI and ATG conditioning with low risk of cific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood
graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell 106:2912–2919, 2005.
transplantation from related and unrelated donors. Blood 114:1099–1109, 2009. 212. Barba P, Martino R, Perez-Simon JA, et al: Combination of the Hematopoietic Cell
186. Baron F, Baker JE, Storb R, et al: Kinetics of engraftment in patients with hematologic Transplantation Comorbidity Index and the European Group for Blood and Marrow
malignancies given allogeneic hematopoietic cell transplantation after nonmyeloabla- Transplantation score allows a better stratification of high-risk patients undergoing
tive conditioning. Blood 104:2254–2262, 2004. reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow
187. Morris E, Thomson K, Craddock C, et al: Outcomes after alemtuzumab-contain- Transplant 20:66–72, 2014.
ing reduced-intensity allogeneic transplantation regimen for relapsed and refractory 213. Barba P, Pinana JL, Martino R, et al: Comparison of two pretransplant predictive mod-
non-Hodgkin lymphoma. Blood 104:3865–3871, 2004. els and a flexible HCT-CI using different cut off points to determine low-, interme-
188. Hill RS, Petersen FB, Storb R, et al: Mixed hematologic chimerism after allogeneic mar- diate-, and high-risk groups: The flexible HCT-CI Is the best predictor of NRM and
row transplantation for severe aplastic anemia is associated with a higher risk of graft OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant
rejection and a lessened incidence of acute graft-versus-host disease. Blood 67:811–816, 16:413–420, 2010.
1986. 214. Pollack SM, Steinberg SM, Odom J, et al: Assessment of the hematopoietic cell
189. Scandling JD, Busque S, Dejbakhsh-Jones S, et al: Tolerance and withdrawal of immu- transplantation comorbidity index in non-Hodgkin lymphoma patients receiving
nosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Mar-
Transplant 12:1133–1145, 2012. row Transplant 15:223–230, 2009.
190. Blume KG, Krance RA: The evaluation and counseling of candidates for hematopoi- 215. Yamamoto W, Ogusa E, Matsumoto K, et al: Predictive value of risk assessment scores
etic cell transplantation, in Thomas’ Hematopoietic Cell Transplantation ed 4, edited by in patients with hematologic malignancies undergoing reduced-intensity conditioning
Appelbaum FR, Forman SJ, Negrin RS, Blume KG, p 445. Wiley-Blackwell, Hoboken, allogeneic stem cell transplantation. Am J Hematol 89:E138–E141, 2014.
NJ, 2009. 216. Nakaya A, Mori T, Tanaka M, et al: Does the hematopoietic cell transplantation specific
191. Thomas ED, Buckner CD, Banaji M, et al: One hundred patients with acute leukemia comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multi-
treated by chemotherapy, total body irradiation, and allogeneic marrow transplanta- center validation study of the Kanto Study Group for Cell Therapy. Biol Blood Marrow
tion. Blood 49:511–533, 1977. Transplant 20:1553–1559, 2014.

Kaushansky_chapter 23_p0353-0382.indd 377 9/19/15 12:47 AM